Management of hepatopulmonary syndrome and portopulmonary hypertension

Targeted pulmonary hypertension therapy is still the cornerstone of management in PoPH. In lieu of liver transplantation in HPS, supplemental oxygen remains the only therapy with proven clinical benefit. Posttransplant critical illness can occur in both PoPH and HPS, through mechanisms that are incompletely understood, with severe consequences for patient survival. Further work understanding PoPH and HPS is necessary to meaningfully improve patient outcomes in these devastating conditions.